Last reviewed · How we verify
PG-011Gel
PG-011Gel is a gene therapy that targets the underlying cause of certain diseases.
PG-011Gel is a gene therapy that targets the underlying cause of certain diseases. Used for Treatment of severe combined immunodeficiency (SCID).
At a glance
| Generic name | PG-011Gel |
|---|---|
| Also known as | PG-011Gel 3% |
| Sponsor | Prime Gene Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Genetics |
| Phase | Phase 3 |
Mechanism of action
It works by delivering a healthy copy of a specific gene to cells, allowing them to produce a functional protein that can help treat or prevent disease. This approach has shown promise in treating a range of conditions, including genetic disorders and certain types of cancer.
Approved indications
- Treatment of severe combined immunodeficiency (SCID)
Common side effects
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |